DNA vaccine and methods for its use

• US 6,472,375 B1
• Filed: 08/31/1998
• Issued: 10/29/2002
• Est. Priority Date: 04/16/1998
• Status: Expired due to Fees

• Current Assignee: John Wayne Cancer Institute
• Original Assignee: John Wayne Cancer Institute
• Inventors: Kaneda, Yasufumi, Hoon, Dave S. B.
• Primary Examiner(s): Priebe, Scott D.
• Assistant Examiner(s): WEHBE, ANNE MARIE SABRINA
• Application Number:
  US09/144,837
• Time in Patent Office: 1,520 Days
• Field of Search: 514/44, 435/320.1, 424/204.1
• US Class Current: 514/44.00R
• CPC Class Codes: A61K 39/001156 Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
• CPC Class Codes: A61K 39/001176 Heat shock proteins
• CPC Class Codes: A61K 39/001186 MAGE
• CPC Class Codes: A61K 39/00119 Melanoma antigens
• CPC Class Codes: A61K 39/001191 Melan-A/MART
• CPC Class Codes: A61K 39/001192 Glycoprotein 100 [Gp100]
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

DNA cancer vaccines and methods for their use are described. The vaccines are comprised of viral liposomes comprising nucleic acid, preferably DNA, encoding a tumor-associated antigen. The viral liposomes may be formed by the fusion of HVJ reagents with nonviral reagents. The vaccine may be administered subcutaneously, intradermally, intramuscularly or into an organ. The vaccine may be administered to induce a host normal cell to express the tumor associated antigen.

Claims

1. A vaccine comprising, in an amount effective to suppress or attenuate melanoma growth upon administration to a human, viral liposomes comprising a fusigenic HVJ polypeptide and DNA encoding a melanoma-associated antigen, wherein said viral liposomes do not include live viral particles.

2. The vaccine of claim 1, further comprising HMG-1.

3. The vaccine of claim 1, further comprising a protein that directs protein or DNA trafficking in the cytoplasm of cells.

4. The vaccine of claim 1, wherein the viral liposomes comprise DNA encoding more than one melanoma-associated antigen.

5. The vaccine of claim 1, further comprising DNA encoding a second immunogenic peptide.

6. The vaccine of claim 1, wherein the melanoma-associated antigen is TRP-2.

12. A method of treating melanoma, the method comprising the step of administering into muscle any one of the compositions of claims 1-11, or 13-33, wherein said intramuscular administration of said composition induces an anti-melanoma immune responses.

13. The vaccine of claim 1, wherein the melanoma-associated antigen is MAGE-1.

14. The vaccine of claim 1, wherein the melanoma-associated antigen is MAGE-3.

15. The vaccine of claim 1, wherein the melanoma-associated antigen is gp-100.

16. The vaccine of claim 1, wherein the melanoma-associated antigen is tyrosinase.

17. The vaccine of claim 1, wherein the melanoma-associated antigen is MART-1.

18. The vaccine of claim 1, wherein the melanoma-associated antigen is HSP-70.

19. The vaccine of claim 1, wherein the melanoma-associated antigen is β

-HCG.

7. A composition comprising viral liposomes prepared from HVJ reagents, wherein:

said liposomes comprise DNA encoding one or more melanoma-associated antigens; and

wherein said liposomes fiurher comprise HMG-1 protein and do not include live viral paticles; and

wherein intramuscular administration of said composition induces an immune response against at least one of said melanoma-associated antigens; and

wherein said immune response is sufficient to suppress or attenuate melanoma growth.

9. The composition of claim 7, wherein one of said melanoma-associated antigens is TRP-2.

20. The composition of claim 7, wherein one of said melanoma-associated antigens is MAGE-1.

21. The composition of claim 7, wherein one of said melanoma-associated antigens is MAGE-3.

22. The composition of claim 7, wherein one of said melanoma-associated antigens is gp-100.

23. The composition of claim 7, wherein one of said melanoma-associated antigens is tyrosinase.

24. The composition of claim 7, wherein one of said melanoma-associated antigens is MART-1.

25. The composition of claim 7, wherein one of said melanoma-associated antigens is HSP-70.

26. The composition of claim 7, wherein one of said melanoma-associated antigens is β

-HCG.

8. A composition comprising viral liposomes prepared from HVJ reagents, wherein:

said liposomes comprise DNA encoding a plurality of melanoma-associated antigens; and

wherein said liposomes further comprise HMG-1 protein and do not include live viral particles; and

wherein intramuscular administration of said composition induces an immune response against at least one of said melanoma-associated antigens.

10. The composition of claim 8, wherein one of said melanoma-associated antigens is TRP-2.

11. The composition of claim 8, comprising a plurality of said melanoma-associated antigens, wherein one of said melanoma-associated antigens is TRP-2 and a second melanoma-associated antigen is gp-100.

27. The composition of claim 8, wherein one of said melanoma-associated antigens is MAGE-1.

28. The composition of claim 8, wherein one of said melanoma-associated antigens is MAGE-3.

29. The composition of claim 8, wherein one of said melanoma-associated antigens is gp-100.

30. The composition of claim 8, wherein one of said melanoma-associated antigens is tyrosinase.

31. The composition of claim 8, wherein one of said melanoma-associated antigens is MART-1.

32. The composition of claim 8, wherein one of said melanoma-associated antigens is HSP-70.

33. The composition of claim 8, wherein one of said melanoma-associated antigens is β

-HCG.